Foundation Showcased in BusinessWeek
| 1 min read

An article today in BusinessWeek online showcases the Foundation's unique business model and its promising investments in pharmaceutical companies to develop drugs for cystic fibrosis. The story highlights the positive early results of an ongoing clinical trial of VX-770, an oral drug that targets the basic defect in CF being developed by Vertex Pharmaceuticals.

Learn more about VX-770.

Share this article
Topics
About the CF Foundation | Genetic Therapies | CFTR Modulators
Recent news
CF Foundation Reflects on Progress Toward Equity, Racial Justice, Diversity, and Inclusion
News | 4 min read
CF Foundation Invests Up to $3.5M in Gensaic for Novel Gene Delivery Method
News | 2 min read
CF Foundation Urges Vertex Pharmaceuticals to Reverse Consequential Decision on Copay Assistance
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe